skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Radiolabeled Monoclonal Antibodies and Hyperthermia. Final Progress Report for November 1, 1998 - April 30, 2003

Technical Report ·
DOI:https://doi.org/10.2172/825909· OSTI ID:825909

The overall objective of this project was to investigate the use of local hyperthermia as a means for improving the potential utility of radiolabeled monoclonal antibodies for tumor therapy. Hyperthermia not only can alter tumor hemodynamics but also can affect antigen expression, catabolism and cytotoxicity. These studies were performed with the human/mouse chimeric anti-tenascin 81C6 antibody in an athymic mouse xenograft model. Variables that were found to be important included the duration and temperature of heating, as well as the timing of the hyperthermia relative to the time of labeled antibody administration.

Research Organization:
Duke University Medical Center, Durham, NC (US)
Sponsoring Organization:
USDOE Office of Energy Research (ER) (US)
DOE Contract Number:
FG02-96ER62148
OSTI ID:
825909
Country of Publication:
United States
Language:
English

Similar Records

Recombinant anti-tenascin antibody constructs
Technical Report · Tue Aug 29 00:00:00 EDT 2006 · OSTI ID:825909

Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy
Journal Article · Wed May 02 00:00:00 EDT 1990 · JNCI, Journal of the National Cancer Institute; (USA) · OSTI ID:825909

Hyperthermia enhances localization of sup 111 In-labeled hapten to bifunctional antibody in human colon tumor xenografts
Journal Article · Fri Mar 01 00:00:00 EST 1991 · Cancer Research; (USA) · OSTI ID:825909

Related Subjects